Darlene Dobkowski, MA | Authors

Articles

Higher Starting Dose of Lenvatinib May Improve HR-QoL Among Patients with RCC

February 12, 2021

“Based on these findings, patients who received lenvatinib 18 mg starting dose had better quality of life and less severe symptoms than those who received lenvatinib 14 mg starting dose,” said Cristiane Decat Bergerot, PhD, MS, BS.

Further Patient Education by Clinicians Is Necessary to Facilitate Better Decision Making

January 28, 2021

“With recent advances in early detection of lung cancer, biomarker testing, and personalized treatment planning, effective patient-provider communication is more important than ever for short- and long-term survivorship,” said Kelly Clark, MA.